David Risinger analyst LEERINK

Currently out of the existing stock ratings of David Risinger, 117 are a BUY (60.31%), 65 are a HOLD (33.51%), 12 are a SELL (6.19%).

David Risinger

Work Performance Price Targets & Ratings Chart

Analyst David Risinger, currently employed at LEERINK, carries an average stock price target met ratio of 73.96% that have a potential upside of 17.93% achieved within 223 days.

David Risinger’s has documented 421 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ABBV, AbbVie at 22-Nov-2024.

Wall Street Analyst David Risinger

Analyst best performing recommendations are on BHC (BAUSCH HEALTH COMPANIES).
The best stock recommendation documented was for ALKS (ALKERMES PLC) at 1/21/2016. The price target of $35 was fulfilled within 1 day with a profit of $1.31 (3.89%) receiving and performance score of 38.88.

Average potential price target upside

ABBV AbbVie AGN Allergan plc ALKS Alkermes Plc BHC Bausch Health Companies ELAN Elanco Animal Health ENDP Endo International PLC GILD Gilead Sciences HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC LLY Eli Lilly and Company MNK Mallinckrodt plc MYL Viatris PRGO Perrigo Company PLC TEVA Teva Pharma Industries Ltd ADR ZTS Zoetis BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson PFE Pfizer PAHC Phibro Animal Health ROIV Roivant Sciences Ltd VTRS Viatris HALO Halozyme Therapeutics MRK Merck mpany RDUS Schnitzer Steel Industries REGN Regeneron Pharmaceuticals TBPH Theravance Biopharma AMGN Amgen VRTX Vertex Pharmaceuticals AMRX Amneal Pharmaceuticals, . Common Stock ASRT Assertio Therapeutics CNTA Centessa Pharmaceuticals PLC ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$206

$23.2 (12.69%)

$153

10 days ago
(22-Nov-2024)

13/14 (92.86%)

$27.92 (15.68%)

293

Buy

$205

$22.2 (12.14%)

17 days ago
(15-Nov-2024)

2/3 (66.67%)

$39.27 (23.70%)

507

Buy

$200

$17.2 (9.41%)

$190

19 days ago
(13-Nov-2024)

12/13 (92.31%)

$28.57 (16.67%)

490

Buy

$224

$41.2 (22.54%)

$231

20 days ago
(12-Nov-2024)

12/15 (80%)

$48.86 (27.90%)

488

Buy

$215

$32.2 (17.61%)

$226

20 days ago
(12-Nov-2024)

8/10 (80%)

$39.86 (22.76%)

293

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is David Risinger is most bullish on?

Potential upside of $326.78 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is David Risinger is most reserved on?

Potential downside of $0.75 has been obtained for TBPH (THERAVANCE BIOPHARMA)

What Year was the first public recommendation made by David Risinger?

On 2007

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?